EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study

Philip A Philip iD, Vaibhav Sahai iD, Nathan Bahary iD, Amit Mahipal iD, Anup Kasi iD, Caio Max S Rocha Lima, Angela T Alistar iD, Paul E Oberstein iD, Talia Golan iD, Jean-Philippe Metges iD, Jill Lacy iD, Christos Fountzilas iD und 9 weitere

Journal of Clinical Oncology · 2024-11 · 42 (31) · 3692-3701

DOI: 10.1200/jco.23.02659 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024-11. Verfasst von Philip A Philip und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Department of Pharmacology, Henry Ford Cancer Institute, Wayne State University School of Medicine, Detroit, MI. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Irinotecan, Antineoplastic Combined Chemotherapy Protocols, Oxaliplatin. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Metastatic pancreatic adenocarcinoma (mPC) remains a difficult-to-treat disease. Fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) is a standard first-line therapy for mPC for patients with a favorable performance status and good organ function. In a phase I study, devimistat (CPI-613) in combination with modified FFX (mFFX) was deemed safe and exhibited promising efficacy in mPC. METHODS The AVENGER 500 trial (ClinicalTrials.gov identifier: NCT03504423 ) is a global, randomized phase III trial conducted at 74 sites across six countries to investigate the efficacy and safety of devimistat in combination with mFFX (experimental arm) compared with standard-dose FFX (control arm) in treatment-naïve patients with mPC. Treatment, administered in once-every-2-weeks cycles until disease progression or intolerable toxicity, included intravenous devimistat at 500 mg/m 2 total per day on days 1 and 3 in the experimental arm. The primary end point of the study was overall survival (OS). RESULTS Five hundred and twenty-eight patients were randomly assigned (266 in the experimental arm and 262 in the control arm). The median OS was 11.10 months for devimistat plus mFFX versus 11.73 months for FFX (hazard ratio [HR], 0.95 [95% CI, 0.77 to 1.18]; P = .655) and median progression-free survival was 7.8 months versus 8.0 months, respectively (HR, 0.99 [95% CI, 0.76 to 1.29]; P = .94). Grade ≥3 treatment-emergent adverse events with >10% frequency in the devimistat plus mFFX arm versus the FFX arm were neutropenia (29.0% v 34.5%), diarrhea (11.2% v 19.6%), hypokalemia (13.1% v 14.9%), anemia (13.9% v 13.6%), thrombocytopenia (11.6% v 13.6%), and fatigue (10.8% v 11.5%), respectively. CONCLUSION Devimistat in combination with mFFX did not improve long- and short-term mPC patient outcomes compared with standard FFX. There were no new toxicity signals with the addition of devimistat.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsIrinotecanAntineoplastic Combined Chemotherapy ProtocolsOxaliplatinAdenocarcinomaLeucovorinHumansMaleFemaleMiddle AgedAgedFluorouracilAdultProgression-Free SurvivalGemcitabine

Substanzen

IrinotecanOxaliplatinLeucovorinFluorouracilGemcitabine

Autor:innen und Institutionen

  • Department of Oncology and Department of Pharmacology, Henry Ford Cancer Institute, Wayne State University School of Medicine, Detroit, MI.
  • University of Michigan Rogel Cancer Center, Ann Arbor, MI.
  • Allegheny Health Network Cancer Institute, Pittsburgh, PA.
  • University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.
  • Division of Medical Oncology, University of Kansas Medical Center, Kansas City, KS.
  • Division of Hematology and Oncology, Atrium Wake Forest Baptist Medical Center, Winston-Salem, NC.

ORCID-Profile: Philip A Philip, Vaibhav Sahai, Nathan Bahary, Amit Mahipal, Anup Kasi, Angela T Alistar, Paul E Oberstein, Talia Golan, Jean-Philippe Metges, Jill Lacy, Christos Fountzilas, Michel Ducreux, Mohamed Salem, Al B Benson, Eric Van Cutsem

Zitieren

APA

Philip, P. A., Sahai, V., Bahary, N., Mahipal, A., Kasi, A., Rocha Lima, C. M. S., Alistar, A. T., Oberstein, P. E., Golan, T., Metges, J. P., Lacy, J., Fountzilas, C., Lopez, C. D., Ducreux, M., Hammel, P., Salem, M., Bajor, D., Benson, A. B., Luther, S., …, & Van Cutsem, E. (2024). Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal of Clinical Oncology, 42(31), 3692-3701. https://doi.org/10.1200/jco.23.02659

Vancouver

Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, et al. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal of Clinical Oncology. 2024;42(31):3692-3701. doi:10.1200/jco.23.02659

BibTeX
@article{Philip2024,
  author = {Philip, Philip A and Sahai, Vaibhav and Bahary, Nathan and Mahipal, Amit and Kasi, Anup and Rocha Lima, Caio Max S and Alistar, Angela T and Oberstein, Paul E and Golan, Talia and Metges, Jean-Philippe and Lacy, Jill and Fountzilas, Christos and Lopez, Charles D and Ducreux, Michel and Hammel, Pascal and Salem, Mohamed and Bajor, David and Benson, Al B and Luther, Sanjeev and Pardee, Timothy and Van Cutsem, Eric},
  title = {Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {31},
  pages = {3692--3701},
  doi = {10.1200/jco.23.02659}
}
Kostenlos starten →